In cancer, PRSS23 is implicated in tumor progression, and it was identified in a systematic network survey of a meta-analysis of breast cancer microarray expression data as one of six genes involved in acquired lapatinib resistance32. This evidence concerns the gene PRSS23 and breast carcinoma.